12-week melatonin intake attenuates cardiac autonomic dysfunction and oxidative stress in multiple sclerosis patients: a randomized controlled trial.
Study Goal
The researchers aimed to investigate the effects of melatonin supplementation on heart rate variability, oxidative stress, systemic inflammation, and sleep in multiple sclerosis patients.
Results Summary
The study compared melatonin supplementation (3 mg/night) to placebo over 12 weeks, measuring changes in HRV, oxidative stress biomarkers, vitamin D levels, and sleep quality, but specific results regarding Dairy were not mentioned in the abstract.
Population
Multiple sclerosis patients (n=27, with 15 in the melatonin group and 12 in the placebo group).
Effective Dosage
3 mg/night
Duration
12 weeks
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin supplementation | neutral | HRV | MS patients | - | investigate the change in | #1 |
melatonin supplementation | neutral | oxidative stress | MS patients | - | investigate the change in | #2 |
melatonin supplementation | neutral | systemic inflammation | MS patients | - | investigate the change in | #3 |
melatonin supplementation | neutral | sleep | MS patients | - | investigate the change in | #4 |
Multiple sclerosis (MS) can induce cardiac autonomic dysfunction identified by a decreased heart rate variability (HRV) which was linked to oxidative stress, vitamin D deficiency and sleep disturbance. Previous MS studies revealed the antioxidant and anti-inflammatory effects of exogenous melatonin, as well as its benefits on sleep and vitamin D. We aimed to investigate the change in HRV, oxidative stress, systemic inflammation and sleep following melatonin supplementation in MS patients. Participants were randomly allocated to either a melatonin group (MG, n = 15) or a placebo group (PG, n = 12) (3 mg/night during 12 weeks). Pre- and post-tests included HRV analysis (Kubios software), sleep dairy and biological analysis [oxidative stress biomarkers (malondialdehyde (MDA), advanced oxidation protein products (AOPP) and reduced glutathione (GSH)); 25-hydroxyvitamin D; C-reactive protein and cholinesterase Gen.2 (CHE2)]. Based on the pre-post supplementation change (Δ